Therapeutics directed against coronavirus

Abstract

This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering one or more polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as, for example, SARS-CoV-1, SARS-CoV-2 or a variant thereof. It is contemplated that the polypeptide can be linked to an amino acid, wherein the compound extends the serum half-life of the amino acid.

What is claimed is: 
     
         1 . A method for treating viral infections, the method comprising administration to a subject in need thereof an antiviral compound linked to a protein that extends the serum half-life of the antiviral compound. 
     
     
         2 . The method of  claim 1 , wherein the protein is selected from the group comprising albumin, transferrin, and the Fc-portion of an antibody. 
     
     
         3 . The method of  claim 1 , wherein the antiviral compound is one or more polypeptides selected from the group comprising SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. 
     
     
         4 . A method for treating viral infections, the method comprising administration to a subject in need thereof one or more polypeptides selected from the group comprising SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. 
     
     
         5 . The method of  claim 4 , wherein the viral infection is caused by a coronavirus. 
     
     
         6 . The method of  claim 5 , wherein the coronavirus is SARS-CoV-1, SARS-CoV-2 or a variant thereof. 
     
     
         7 . The method of  claim 4 , wherein the polypeptides further comprises a compound linked to the amino acid, wherein the compound extends the serum half-life of the amino acid. 
     
     
         8 . The method of  claim 7 , wherein the compound is albumin, transferrin, or the Fc-portion of an antibody. 
     
     
         9 . A method for preventing viral infections, the method comprising administration to a subject in need thereof one or more polypeptides selected from the group comprising SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. 
     
     
         10 . The method of  claim 9 , wherein the viral infection is caused by a coronavirus. 
     
     
         11 . The method of  claim 10 , wherein the coronavirus is SARS-CoV-1, SARS-CoV-2 or a variant thereof. 
     
     
         12 . The method of  claim 9 , wherein the polypeptides further comprise a compound linked to the amino acid, wherein the compound extends the serum half-life of the amino acid. 
     
     
         13 . The method of  claim 12 , wherein the compound is albumin, transferrin, or the Fc-portion of an antibody.